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Abstract
Background: Point-of-care (POC) devices could be used 
to measure hemoglobin A1c (HbA1c) in the doctors’ office, 
allowing immediate feedback of results to patients. 
Reports have raised concerns about the analytical perfor-
mance of some of these devices. We carried out a system-
atic review and meta-analysis using a novel approach to 
compare the accuracy and precision of POC HbA1c devices.
Methods: Medline, Embase and Web of Science databases 
were searched in June 2015 for published reports com-
paring POC HbA1c devices with laboratory methods. Two 
reviewers screened articles and extracted data on bias, 
precision and diagnostic accuracy. Mean bias and varia-
bility between the POC and laboratory test were combined 
in a meta-analysis. Study quality was assessed using the 
QUADAS2 tool.
Results: Two researchers independently reviewed 1739 
records for eligibility. Sixty-one studies were included in 
the meta-analysis of mean bias. Devices evaluated were 
A1cgear, A1cNow, Afinion, B-analyst, Clover, Cobas b101, 
DCA 2000/Vantage, HemoCue, Innovastar, Nycocard, 
Quo-Lab, Quo-Test and SDA1cCare. Nine devices had 
a negative mean bias which was significant for three 
devices. There was substantial variability in bias within 
devices. There was no difference in bias between clinical 
or laboratory operators in two devices.
Conclusions: This is the first meta-analysis to directly 
compare performance of POC HbA1c devices. Use of a 
device with a mean negative bias compared to a labora-
tory method may lead to higher levels of glycemia and a 
lower risk of hypoglycaemia. The implications of this on 
clinical decision-making and patient outcomes now need 
to be tested in a randomized trial.
Keywords: diabetes; HbA1c; instrument performance; 
meta-analysis; point-of-care testing; systematic review.
Introduction
Regular monitoring of glycated hemoglobin subfrac-
tion A1c (HbA1c) in people with diabetes and treatment 
with glucose-lowering medications to improve glycaemic 
control can reduce the risk of developing complications 
[1]. In 2011, a World Health Organization consultation con-
cluded that HbA1c at a threshold of 6.5% (48 mmol/mol) 
can be used as a diagnostic test for diabetes [2]. HbA1c 
monitoring often requires the patient to attend the health 
center twice: once to have blood taken and then returning 
to get test results and receive adjustments to medication.
Point-of-care (POC) analysers are bench-top instru-
ments that use a finger-prick blood sample and are 
designed for use in a treatment room or at the bed-side. 
They provide a test result within a few minutes allowing 
clinical decisions and medication changes to take place 
immediately. The suitability of many of these devices 
for the accurate measurement of HbA1c has been ques-
tioned, with some POC HbA1c test devices reported not to 
meet accepted accuracy and precision criteria [3]. Ideal 
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imprecision goals for HbA1c should be coefficient of varia-
tion (CV) of  < 2% for HbA1c reported in % units (or  < 3% in 
SI units, mmol/mol) [4–6].
Most evaluations of POC HbA1c devices have taken 
place in laboratory settings [7, 8]; fewer studies have 
assessed device performance in a POC setting or with cli-
nicians performing the tests [9, 10]. The only published 
review that has attempted to combine data from accuracy 
studies identified five studies covering three devices and 
compared correlation coefficients [11]. Systematically 
reporting and pooling data estimates of bias and preci-
sion between POC HbA1c devices and laboratory measure-
ments would enable end users to assess which analysers 
best meet their analytical performance needs. This may be 
of particular importance for clinicians in primary care set-
tings where much of the management of diabetes patients 
takes place. The comparison of accuracy between devices 
over the entire therapeutic range would need to be carried 
out by combining data on measurement error (bias) 
between POC and laboratory tests [12].
The aim of this study was to compare accuracy and 
precision of POC HbA1c devices with the local laboratory 
method based on data from published studies and discuss 
the clinical implications of the findings.
Materials and methods
Data sources and searches
The protocol was registered on the PROSPERO database 
(Registration number CRD42013006678). Searches of 
MEDLINE (1950–2015), EMBASE (1980–2015) and Web of 
Science databases (1900–2015) were carried out in June 
2015 using search terms for glycated hemoglobin and 
POC device names, and Medical Subject Headings for POC 
systems (Medline search strategy in Table 1, Supplemen-
tary Data). Hand searches of original articles, reviews and 
conference abstracts were also carried out. Reports in all 
languages published in peer-reviewed journals were con-
sidered for inclusion.
Study selection
Title and abstract review of retrieved references and 
screening of full texts for eligibility were performed by two 
reviewers (JH and JM).
Included studies performed both a POC HbA1c test 
(defined as any instrument designed to provide a rapid 
quantitative measurement of HbA1c using capillary blood 
at the point of care) and laboratory-based methods on 
each sample and reported mean difference between POC 
and laboratory HbA1c (referred to hereafter as compara-
tor method). The mean difference (or mean bias) from 
included studies was obtained using methods described 
by Bland and Altman for assessing agreement between 
two methods [13]. Studies were excluded if the study 
did not evaluate the accuracy of HbA1c POC devices, if 
there was no comparator test, if the article was not peer 
reviewed, data could not be extracted, patients had hemo-
globinopathies or if the POC analysers evaluated were not 
commercially available on 30 June 2015.
Data extraction and quality assessment
Data were extracted by two reviewers on the following: 
sample type (capillary or venous blood), operator (clinical 
or laboratory operator), setting (point of care, laboratory 
or other), number of participants, mean HbA1c (in either 
SI, mmol/mol or % units) and mean (±standard deviation, 
SD) bias, defined as mean of the difference between POC 
and comparator method (POC-comparator) for each HbA1c 
sample measured. Reviewers were not blinded to any 
aspects of the studies during data extraction. Disagree-
ments were resolved by discussion or, if consensus could 
not be reached, discussion with a third reviewer. If dupli-
cate POC tests were performed using different reagent lot 
numbers, then both comparisons were included in the 
meta-analysis.
Instrument-specific data were extracted: POC device 
make and model, make and model of comparator method 
used and whether the comparator method was carried out 
in a NGSP (National Glycohemoglobin Standardization 
Program) or IFCC (International Federation for Clinical 
Chemistry and Laboratory Medicine) reference laboratory.
Study quality and risk of bias in data collection and 
methodology were graded using the QUADAS 2 risk of bias 
table [14]. Funding by device manufacturer and whether 
the range in HbA1c was sufficiently broad (defined as 
5%–11% or 31–97 mmol/mol) were recorded. All studies 
deemed to be at high risk of bias for at least one criterion 
were excluded in a sensitivity analysis.
Data on the diagnostic accuracy of devices at a thresh-
old of 6.5% (48 mmol/mol) was requested from study 
authors. Where data were not available, diagnostic accu-
racy was estimated from correlation and Bland-Altman 
graphs by counting the number of points in graph quad-
rants representative of diagnoses that would be truly neg-
ative, falsely positive, truly positive and falsely negative.
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Data on imprecision recorded as CV was extracted 
in % units where reported. We combined both within 
and between-run precision at low ( < 6%, 42 mmol/mol), 
medium (6%–8%, 42–64 mmol/mol), and high ( ≥ 8%, 64 
mmol/mol) levels of HbA1c as well as total CV regardless 
of whether the samples were control samples or patient 
samples. The mean imprecision was combined by taking 
the average for each device at each level of HbA1c. Impreci-
sion data on comparator instruments was also combined 
where this was reported.
Data synthesis and analysis
All analyses were carried out using Stata 12.0SE (Stata-
Corp, College Station, TX, USA). Data on mean bias 
between POC and laboratory HbA1c and SD mean bias were 
combined using random effects DerSimonian and Laird 
meta-analysis [15] as recommended for meta-analyses of 
method comparison studies with considerable heteroge-
neity [16]. Data for each POC instrument were separately 
pooled. The following estimates were made: median dif-
ference was approximated to mean bias; if SD or standard 
error were not reported, then these were imputed averag-
ing the SD from studies of the same device [17]. The SD of 
the mean bias and the standard error of the SD [18] were 
pooled in a separate meta-analysis to explore the variabil-
ity in bias within each device. In a descriptive analysis, we 
reported bias and SD for each device without pooling. In 
meta-analyses, we summarized mean bias for each device 
and SD for each device with 95% confidence intervals. 
Because performance may vary between different clinical 
settings, we also show 95% prediction intervals (using the 
“rfdist” command in Stata) to display the estimated uncer-
tainty about the mean bias, and SD, in any future study 
[19]. Studies in which estimates were made, those at high 
risk of bias and those in which HbA1c measurement were 
carried out more than 24 h apart were excluded in sensi-
tivity analyses. Sensitivity analyses including only reports 
which used NGSP or IFCC reference laboratories for the 
comparator HbA1c and those published in 2014–2015 were 
also conducted. Subgroup analyses were performed where 
possible to explore differences between operator (clinical 
or laboratory), setting (POC or laboratory), adults or chil-
dren or blood sample type (venous or capillary) within a 
single device. Meta-regression was used where there were 
sufficient studies to establish whether different settings 
(POC or laboratory) or study publication year significantly 
affected the mean bias. A post hoc meta-regression was 
carried out to explore the effect of publication year on SD 
of the bias in the DCA device.
Where there were sufficient data, a bivariate random-
effects method was used to estimate average sensitivity 
and specificity using the “metandi” command in Stata 
[20]. The average sensitivity and specificity was calculated 
and hierarchical summary receiver-operating characteris-
tic curves were plotted to display the diagnostic accuracy 
across studies within a device.
Results
Searches identified 1739 records, a further six records were 
identified from scanning reference lists. There were 435 
duplicates, and 1063 records were excluded after title and 
abstract review and 181 after full text review, leaving 66 
studies; a further six studies were excluded because they 
included people with hemoglobin variants or data could 
not be extracted. Sixty studies were included in the anal-
ysis of mean bias from 13 devices (Supplementary Data, 
Figure 1). Forty-five included papers were full text articles, 
the remainder were conference abstracts, letters or com-
ments. Twenty-five studies were carried out in Europe, 16 
in the Americas, nine in Asia, eight in Australia and two 
unknown. Four articles were non-English and required 
translation [21–24]. Seven studies were conducted in chil-
dren [25–31]. Some studies reported results from multiple 
devices or multiple lot numbers giving 105 comparisons in 
the meta-analysis. Characteristics of all included studies 
are shown in Table 1.
Devices compared in the meta-analysis were A1cgear 
(n = 1), A1cNow (n = 17), Afinion (n = 12), B-analyst (n = 5), 
Clover (n = 2), Cobas b101 (n = 5), DCA 2000/Vantage 
(n = 39), HemoCue (n = 2), Innovastar (n = 5), Nycocard 
(n = 6), Quo-Lab (n = 3), Quo-Test (n = 7), and SDA1cCare 
(n = 1). The majority of studies reported bias in HbA1c in 
% units; only two studies reporting in mmol/mol [34, 62]. 
Nineteen studies were carried out in a laboratory setting 
by laboratory staff, 21 studies were carried out at point of 
care and in 12 studies, a clinician operated the POC device.
Mean bias and 2SD range of difference in HbA1c 
between each POC device and comparator method 
(Figure  1) shows that there is a large variability in bias 
for most devices. Pooling data on mean bias (Figure 2) in 
a meta-analysis shows that nine devices have a negative 
mean bias; this was significant for three devices (Quo-
Lab, DCA and InnovaStar). Four devices had a positive 
mean bias which was significant for two devices (B-ana-
lyst and SDA1cCare). Heterogeneity between studies 
was large for all devices, with I2 ranging from 67.5% to 
99.5%. Although the pooled mean bias for some devices 
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was small across all studies, bias within a single device 
could vary substantially between studies. For example, 
the mean bias across studies was –0.05% HbA1c for the 
A1cNow device, but it varied from –0.70% (95% confi-
dence interval, CI –0.82 to 0.58%) [56] to +0.67% (95% 
CI 0.52–0.82%) [21]. Similarly for the DCA device, mean 
bias varied from –0.96% to +0.28%. Even when the mean 
bias was small, individual differences in measurements 
within a single study could be larger, as shown by the 
two SD bars (Figure 1), which typically extended over a 
range of 1%–1.5% HbA1c (10.9–16.4 mmol/mol). Moreover, 
the width of the prediction intervals in Figure 2 indicate 
that for most devices the mean bias of a future study 
could vary widely. Summary estimates of the SD of the 
differences (Figure  3) ranged from 0.21% to 0.53% but 
again individual SDs could be larger and varied between 
studies. Meta-regression did not find that year of publi-
cation significantly affected the mean bias for any of the 
devices but there was a trend towards a less negative bias 
over time in the DCA device (coefficient 0.014% HbA1c per 
year, p = 0.081). A post hoc meta-regression found that the 
standard deviation of the bias in the DCA device signifi-
cantly decreased over time (–0.01% HbA1c per year, 95% 
CI –0.015 to –0.006, p < 0.0001), suggesting that the vari-
ability in measurements contributing to the mean bias in 
the DCA device is decreasing over time. A subgroup anal-
ysis to compare the size of the SD in studies published 
prior to 2006 with those published between 2006 and 
2015 found that those published in the last 10 years had 
a mean SD of 0.33% (95% CI 0.30–0.37) HbA1c compared 
with a SD of 0.45% (95% CI 0.38–0.52) HbA1c before 2006.
Sensitivity analyses excluding studies in which 
approximations were necessary during data extrac-
tion and those at highest risk of bias (Supplementary 
Data, Figures 2 and 3) gave broadly similar results. Nine 
studies which used NGSP or IFCC reference laboratories 
for the comparator method no longer had data for three 
devices (A1cGear, HemoCue and SDA1cCare). There was 
no longer a significant mean bias for the DCA device and 
variability was lower (mean bias 0.00%, 95% CI –0.16 to 
0.15), whereas the Quo-Test had a significantly negative 
bias (mean bias –0.27%, 95% CI –0.50 to –0.03) (Supple-
mentary Data, Figure 4). Studies published in 2014–2015 
also had a non-significant mean bias for the DCA device 
(–0.08%, 95% CI –0.21 to 0.06).
Subgroup analyses for the DCA device comparing 
different settings found no difference in mean bias in 
studies carried out in a point of care setting –0.27% (95% 
CI –0.38 to –0.16) compared with a laboratory setting 
–0.30% (95% CI –0.47 to –0.14). Similarly, mean bias 
in studies carried out by a laboratory operator was not Au
th
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Figure 1: Forest plot showing mean bias (in % HbA1c)±2SD of HbA1c measured using point-of-care devices compared with laboratory tests, by 
POC device, ordered by mean bias.
significantly  different from that in those carried out by 
a clinical operator (–0.30%, 95% CI –0.47 to –0.14 vs. 
–0.30%, 95% CI –0.42 to –0.18, p = 0.956) (Supplementary 
Data, Figure 5).  Sensitivity analysis gave similar results 
(not shown). Subgroup analyses carried out for the 
A1cNow device also found no differences in mean bias 
 - 10.1515/cclm-2016-0303
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for different operators or settings (results not shown). 
There was no difference in bias in six studies carried 
out in children compared with 30 studies carried out 
in adults on the DCA device (–0.24%, 95% CI –0.33 to 
–0.16 in adults compared with –0.30%, –0.50 to –0.10 in 
children). There was no difference in mean bias between 
venous or capillary blood in the A1cNow or DCA (Supple-
mentary Data, Figures 6 and 7).
Figure 2: Forest plot showing mean bias (in % HbA1c) and 95% CI and prediction intervals, by POC device, ordered by mean bias.
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There were sufficient data to carry out meta-analysis 
on diagnostic accuracy for five devices (Afinion, DCA, 
A1cNow, Quo-Test and Nycocard). Sensitivity across all 
the devices was similar, although specificity varied more, 
with the Afinion and DCA having the highest specificity 
at a cutoff of 6.5% HbA1c (48 mmol/mol) (Supplementary 
Figure 3: Forest plot showing standard deviation of differences, 95% confidence intervals of SD and prediction intervals for included 
studies, by POC device, ordered by SD.
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Data, Table 2 and Figure 8). Repeating this analysis only 
in studies published from 2006 to 2015 did not change the 
results.
Imprecision measured using replicate analyses of 
a single sample for each analyzer at low, medium and 
high HbA1c are presented as mean CV in the Supplemen-
tary Data (Table 3). All devices bar one which only had a 
single evaluation had mean CVs above 2% at low HbA1c 
values (lower than 6% HbA1c, 42 mmol/mol). At high HbA1c 
(above 8% HbA1c, 64mmol/mol), mean CV was  < 2% for 4 
devices, all of which only included data from one study. 
Five devices had a total CV  < 2%. Only two devices had 
all measured CVs below 2% (Cobas b101 and A1cgear) 
but both of these were only based on a single evaluation. 
Imprecision of comparator methods is shown in Table 4 
in Supplementary Data. Each CV was from a single study, 
in some cases using multiple data points from repeat 
analysis of different samples. CVs ranged from 0.8% for 
Tosoh (model not specified) to 2.3% for the Diamat instru-
ment. Between-laboratory precision reported in the 2016 
CAP survey [77] is shown for the comparator methods and 
Afinion, DCA 2000 and DCA Vantage devices in Table 4 in 
Supplementary Data which range from 1.6% for the Tosoh 
G8 to 3.1% for Afinion.
Study quality/risk of bias
Sixteen studies reported receiving funding from the POC 
device manufacturers [7, 9, 27, 30, 35, 36, 39, 41, 47, 50, 51, 
56, 58, 59, 65, 70]. In 18 of the included studies, the instru-
ment was provided free of charge by the manufacturers [3, 
7, 9, 24, 27, 31, 36, 38, 39, 44, 50, 53, 54, 56, 59, 65, 69, 70]. In 
eight studies, it was unclear what laboratory methodology 
was used in the comparator method [22, 33, 35, 41, 43, 51, 61, 
74]. Another seven studies did not use a wide range of HbA1c 
concentrations to assess mean bias across all HbA1c concen-
trations [24, 25, 41, 50, 57, 71, 73]. Nine studies used an NGSP- 
or IFCC-certified laboratory for the comparator method [3, 7, 
29, 41, 50, 54, 56, 59, 60].
Discussion
This analysis has shown that the majority of POC HbA1c 
devices have a mean negative bias compared to laboratory 
methods. Devices with the most comparisons were found to 
have higher specificity, rather than consistently high sen-
sitivity, for detecting HbA1c above the diagnostic threshold. 
Unexplained variation in the mean bias was also observed 
for most devices, as indicated by large variations in SDs 
of the bias as well as high imprecision from the repeated 
analysis of the same sample. This is the first meta-analysis 
to compare performance between HbA1c measured using 
POC devices and laboratory methods drawn from pub-
lished data. We have used a novel approach to pool data 
on mean bias, variability, device precision and sensitiv-
ity and specificity. Our analysis has demonstrated that 
differences between POC HbA1c and comparator methods 
can vary considerably within a single device across all the 
included studies with POC values ranging from as much 
as 1.5% HbA1c below to 1.5% HbA1c above the comparator 
method HbA1c across all devices.
Many evaluations included in our review compared 
capillary blood on the POC device with venous blood on 
the comparator method. Although there may be slight 
differences in HbA1c in different sample types [78, 79] we 
have been able to eliminate this as a source of bias in two 
devices (A1cNow and DCA). We did not find evidence that 
changes in calibration over time resulted in significantly 
lower levels of bias in device; however, these data sug-
gests that variability in the DCA device may be improv-
ing over time, suggesting that its precision may also have 
improved over time. The diagnostic accuracy of devices 
was not affected when only the most recent studies were 
included.
Acceptable limits for bias and imprecision vary 
between organizations; the College of American Patholo-
gists (CAP) criteria state that acceptable limits of bias are 
±6% [80], whereas a within-laboratory CV of  < 2% (in % 
units) is widely recommended [4, 80]. More recently, the 
IFCC Task Force on HbA1c Standardization have recom-
mended using a sigma metrics approach to evaluating 
analytical error. This takes into account both bias and 
imprecision in one model based on total allowable error, 
where bias and imprecision are not treated as separate 
performance measures [81]. The CAP survey [80] includes 
data from HbA1c POC devices and shows comparable per-
formance to a number of routine laboratory analysers. 
However, the survey is aimed at clinical laboratories and 
participation is not mandatory for instruments used in 
non-laboratory settings. Those that enter the survey may 
therefore be a self-selecting group and under-represent 
the true extent of the use of POC devices in the USA.
Limitations
Sensitivity and specificity at the diagnostic threshold 
(6.5% HbA1c, 48 mmol/mol) were not reported in the 
included papers. However, we have been able to combine 
 - 10.1515/cclm-2016-0303
Downloaded from De Gruyter Online at 09/28/2016 01:03:45PM
via University of East Anglia
Hirst et al.: A systematic review and meta-analysis      11
data from plots and unpublished data from authors to 
compare sensitivity and specificity of five devices at the 
diagnostic threshold.
Some laboratory instruments have been reported 
to have systematic biases against reference laboratories 
[46] which may have led to under- or over-estimation of 
biases in some studies in our review. Only nine studies 
reported to use an NGSP or IFCC reference laboratory for 
the comparator method which generally resulted in lower 
variability. The actual number of studies using reference 
laboratories may have been higher as many of the papers 
included in this review were conference abstracts which 
were limited by word count.
Even though the intended end-users of POC devices 
are clinicians or healthcare workers, the majority of the 
accuracy studies were carried out in a laboratory setting 
by laboratory staff. The translatability of the evaluations 
included in the meta-analysis to the clinical end-user is 
therefore a major limitation of this study. We have been 
able to examine the impact of operator and setting on bias 
for two devices, DCA and A1cNow, both of which showed 
no significant difference in performance between a clinical 
and laboratory operator. It is important to note that prac-
tices and regulations in POC testing vary between coun-
tries and therefore POC testing may impact differently on 
patient management between geographic locations.
Mean values from duplicate POC tests were used by 
some researchers [64], and this may lead to the reported 
variability being lower than actual variability. In some 
studies, it was not clear whether results were reported as 
relative mean bias or absolute mean bias; however, we 
have excluded studies with unclear reporting in a sensi-
tivity analysis and found similar results.
Clinical implications
Because the majority of devices had an overall negative 
bias as well as large standard deviations, their use in a 
clinical setting may result in differences in treatment deci-
sions compared with results from laboratory comparator 
methods. POC HbA1c results which are lower than labora-
tory methods may result in undertreatment in some cases. 
The implications of this on overall patient care may result 
in fewer short-term hypoglycemic episodes, however, the 
long-term use may leave some patients exposed to higher 
than optimal levels of glycemia. The long-term effects of 
this are not known, but studies have shown that even 
small increases in HbA1c increase the risk of micro- and 
macrovascular complications [1]. This may be outweighed 
by the other benefits of POC testing including improved 
ability of the clinicians to make appropriate and timely 
treatment decisions [82, 83]. There was insufficient pub-
lished data to enable comparison of performance between 
settings and operators for most devices; further evalua-
tions in a clinical setting are now needed.
As well as bias, good reproducibility or precision is 
crucial in device performance; however, imprecision in 
nearly all devices was poor with the majority of devices 
having mean CVs  > 2% at low HbA1c levels. In contrast, 
only one of the comparator instruments had a mean CV 
over 2%. These imprecision data are based on repeated 
analysis of a single sample; our review has shown that 
there is also considerable variability in HbA1c results in 
most devices in evaluations over a range of HbA1c concen-
trations which may better represent clinical situations. 
These high levels of uncertainty in results may mean that 
some real changes in HbA1c may not be picked up and 
could result in different treatment decisions. The combi-
nation of instrument performance and biological variabil-
ity in HbA1c [84] could substantially affect the numbers 
of patients diagnosed with diabetes and impact on clini-
cal decision making for those with established diabetes. 
These high levels of imprecision and the large variability 
is a key finding of this review and may be a crucial factor 
influencing the adoption of these technologies.
This analysis contributes to the information avail-
able to clinicians who are considering whether to use POC 
HbA1c testing. The decision to select an analyzer must be 
carefully considered based on clinical needs and what is 
deemed to be acceptable bias and precision of the ana-
lyser. The NGSP recommends that for method certifica-
tion 37 out of 40 HbA1c tests should be within ±6% relative 
to the standard reference laboratory measurement [80]. 
Our analysis shows that the mean measurement bias of 
two devices was  > 6% relative to the comparator method, 
however, because of the large variability observed within 
devices it is probable that many of the devices will give 
some measurements greater or  < 6% of the patient’s true 
HbA1c. It is therefore likely that some of the devices would 
fail to meet the requirements of 37 of 40 test results within 
6% of reference laboratory measurements.
The impact of using POC HbA1c testing on medica-
tion use, clinical decision making and patient outcomes 
now needs to be evaluated in a randomized trial with full 
 economic evaluation.
Acknowledgments: This report is independent research 
supported by the National Institute for Health Research 
(NIHR) (Doctoral Research Fellowship, Ms Jennifer Hirst, 
DRF-2013-06-086). The views expressed in this publica-
tion are those of the author(s) and not necessarily those of 
 - 10.1515/cclm-2016-0303
Downloaded from De Gruyter Online at 09/28/2016 01:03:45PM
via University of East Anglia
12      Hirst et al.: A systematic review and meta-analysis
the NHS, NIHR or the Department of Health. We are grate-
ful to Dr. Erna Lenters-Westra, Samir Malkani,  Bernard 
Vialettes and Katrina Ruedy on behalf of Jamie Wood for 
providing us with unpublished data. We also thank Ms. 
Nia Roberts for her assistance in optimizing the search 
strategy.
Author contributions: All the authors have accepted 
responsibility for the entire content of this submitted 
manuscript and approved submission. J.H. designed the 
study, researched data, conducted the analyis and wrote 
manuscript, J.M. researched data and reviewed/edited 
manuscript. C.P. reviewed/edited manuscript and contrib-
uted to discussion. E.E. reviewed/edited manuscript and 
contributed to discussion. B.F. researched data, contrib-
uted to the analysis and reviewed/edited manuscript. R.S. 
contributed to the analysis, reviewed/edited manuscript 
and contributed to discussion. A.F. reviewed/edited man-
uscript and contributed to discussion.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: C.P. is a member of the NIHR Diag-
nostic Evidence Co-operative Oxford. The views expressed 
are those of the authors and not necessarily those of the 
NHS, the NIHR or the Department of Health. The funding 
organization(s) played no role in thestudy design; in 
the collection, analysis, and interpretationof data; in 
the writing of the report; or in the decision tosubmit the 
report for publication. The researchers retained complete 
independence in the conduct of this study. A.F. is an NIHR 
Senior Investigator.
References
1. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, 
et al. Association of glycaemia with macrovascular and microvas-
cular complications of type 2 diabetes (UKPDS 35): prospective 
observational study. BMJ 2000;321:405–12.
2. WHO. Use of glycated haemoglobin (HbA1c) in the diagnosis of 
diabetes mellitus, 4 December 2014. Available at: http://www.
who.int/diabetes/publications/report-hba1c_2011.pdf.
3. Lenters-Westra E, Slingerland RJ. Six of eight hemoglobin A1c 
point-of-care instruments do not meet the general accepted 
analytical performance criteria. Clin Chem 2010;56:44–52.
4. Goodall I, Colman PG, Schneider HG, McLean M, Barker G. Desir-
able performance standards for HbA(1c) analysis – precision, 
accuracy and standardisation: consensus statement of the Aus-
tralasian Association of Clinical Biochemists (AACB), the Austral-
ian Diabetes Society (ADS), the Royal College of Pathologists of 
Australasia (RCPA), Endocrine Society of Australia (ESA), and the 
Australian Diabetes Educators Association (ADEA). Clin Chem Lab 
Med 2007;45:1083–97.
5. Weykamp CW, Mosca A, Gillery P, Panteghini M. The analyti-
cal goals for hemoglobin A(1c) measurement in IFCC units and 
National Glycohemoglobin Standardization Program Units are 
different. Clin Chem 2011;57:1204–6.
6. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirk-
man MS, et al. Guidelines and recommendations for laboratory 
analysis in the diagnosis and management of diabetes mellitus. 
Clin Chem 2011;57:e1–47.
7. Lenters-Westra E, Slingerland RJ. Three of 7 hemoglobin A1c 
point-of-care instruments do not meet generally accepted ana-
lytical performance criteria. Clin Chem 2014;60:1062–72.
8. Petersen JR, Omoruyi FO, Mohammad AA, Shea TJ, Okorodudu AO, 
Ju H. Hemoglobin A1c: assessment of three POC analyzers relative 
to a central laboratory method. Clin Chim Acta 2010;411:2062–6.
9. St John A, Davis TM, Goodall I, Townsend MA, Price CP. Nurse-
based evaluation of point-of-care assays for glycated haemoglo-
bin. Clin Chim Acta 2006;365:257–63.
10. Wood JA, Kaminski BM, Kollman C, Diabetes P. The accuracy 
and precision of the axis-shield afinion HbA1c measure ment 
device. Diabetes 2011; Conference: 71st Scientific Sessions of 
the American Diabetes Association San Diego, CA United States. 
Conference Start: 20110624 Conference End: 20110628. Confer-
ence Publication: (var.pagings). 60:A237.
11. Health Quality Ontario. Point-of-care hemoglobin A1c testing: 
an evidence-based analysis. Ont Health Technol Assess Ser 
2014;14:1–30.
12. Wan Y, Heneghan C, Stevens R, McManus RJ, Ward A, Perera R, 
et al. Determining which automatic digital blood pressure device 
performs adequately: a systematic review. J Hum Hypertens 
2010;24:431–8.
13. Bland JM, Altman DG. Statistical methods for assessing agree-
ment between two methods of clinical measurement. Lancet 
1986;1:307–10.
14. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, 
Reitsma JB, et al. QUADAS-2: a revised tool for the quality 
assessment of diagnostic accuracy studies. Ann Intern Med 
2011;155:529–36.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control 
Clin Trials 1986;7:177–88.
16. Williamson PR, Lancaster GA, Craig JV, Smyth RL. Meta-analysis 
of method comparison studies. Stat Med 2002;21:2013–25.
17. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic 
Reviews of Interventions Version 5.1.0 [updated March 2011]. The 
Cochrane Collaboration, 2011. Available from www.handbook.
cochrane.org.
18. Ahn S, Fessler JA. Standard errors of mean, variance, and stand-
ard deviation estimators. EECS Department, The University of 
Michigan, 2003:1–2.
19. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects 
meta-analyses. BMJ 2011;342:d549.
20. Harbord RM, Whiting P. Metandi: meta-analysis of diagnos-
tic accuracy using hierarchical logistic regression. Stata J 
2009;9:211–29.
21. Affret A, Griz LH, Cesse EA, Specht YD, Carvalho EM, Fontbonne 
A. Assessment of a glycated hemoglobin point-of-care analyzer 
(A1CNow+) in comparison with an immunoturbidimetric method: 
a diagnostic accuracy study. Sao Paulo Med J 2015;133:460–4.
22. Boz M, Gerard P, Scheen AJ, Lefebvre PJ, Castillo MJ. Rapid 
determination by immunoassay of glycosylated hemoglobin in 
capillary blood compared to an affinity method for boronate and 
 - 10.1515/cclm-2016-0303
Downloaded from De Gruyter Online at 09/28/2016 01:03:45PM
via University of East Anglia
Hirst et al.: A systematic review and meta-analysis      13
ion capturing on venous blood. [French]. Ann Biol Clin (Paris) 
1997;55:139–44.
23. Carrera Font MT, Sole Brichs MC, Sala Alvarez MC, Navarro 
Olivella JM, Servent Turo J, Felipe Fernandez MP. Capillary HbA1c 
determination on type 2 diabetes patients in a primary health 
centre. [Spanish]. Aten Primaria 2011;43:536–43.
24. Villar-del-Campo MC, Rodriguez-Caravaca G, Gil-Yonte P, 
Cidoncha-Calderon E, Garcia-Cruces Mendez J, Donnay-Perez S. 
[Diagnostic agreement between two glycosylated a1b hemo-
globin methods in Primary Care]. Semergen 2014;40:431–5.
25. Chan CL, McFann K, Newnes L, Nadeau KJ, Zeitler PS, Kelsey M. 
Hemoglobin A1c assay variations and implications for diabetes 
screening in obese youth. Pediatr Diabetes 2014;15:557–63.
26. El Arabi H, Willems D, Melot C, Dorchy H. [Evaluation of DCA 
vantage for rapid in-clinic measurement of HbA1c on capil-
lary blood in young type 1 diabetic patients]. Rev Med Brux 
2013;34:87–9.
27. Greaves RF, Northfield J-A, Cameron FJ. Haemoglobin A1c: evalu-
ation of three point of care analysers for use in a paediatric 
diabetes clinic. Ann Clin Biochem 2005;42(Pt 2):124–9.
28. Pope RM, Apps JM, Page MD, Allen K, Bodansky HJ. A novel 
device for the rapid in-clinic measurement of haemoglobin A1c. 
Diabet Med 1993;10:260–3.
29. Tamborlane WV, Kollman C, Steffes MW, Ruedy KJ, Dongyuan X, 
Beck RW, et al. Comparison of fingerstick hemoglobin A1c levels 
assayed by DCA 2000 with the DCCT/EDIC central laboratory 
assay: results of a Diabetes Research in Children Network (Direc-
Net) Study. Pediatr Diabetes 2005;6:13–6.
30. Wood JR, Kaminski BM, Kollman C, Beck RW, Hall CA, Yun 
JP, et al. Accuracy and precision of the Axis-Shield Afinion 
hemoglobin A1c measurement device. J Diabetes Sci Technol 
2012;6:380–6.
31. Dupuy AM, Elong-Bertard C, Badiou S, Barrot A, Bargnoux AS, 
Cristol JP. Analytical performance and clinical use of a hemo-
globin A1c point-of-care analyzer in a pediatric unit. J Diabetes 
Sci Technol 2013;7:1408–9.
32. Arsie MP, Marchioro L, Lapolla A, Giacchetto GF, Bordin MR, 
Rizzotti P, et al. Evaluation of diagnostic reliability of DCA 2000 
for rapid and simple monitoring of HbA1c. Acta Diabetologica 
2000;37:1–7.
33. Azevedo T, Ferreira M, Giestas A, Carvalho AC, Pinto S, Palma I. 
HbA1c-evaluation of the DCA2000 and quo-test systems. Endo-
crine Reviews Conference: 93rd Annual Meeting and Expo of the 
Endocrine Society, ENDO 2011;32(3 Meeting Abstracts).
34. Berry H, Hall G, Donovan J. Comparison of point of care haemo-
globin A1c meters. Clin Chem Lab Med 2014;52:eA326–7.
35. Cagliero E, Levina EV, Nathan DM. Immediate feedback of HbA1c 
levels improves glycemic control in type 1 and insulin-treated 
type 2 diabetic patients. Diabetes Care 1999;22:1785–9.
36. Clark AL, Irvin BR, Isbell AW, Ammirati EA. Multi-site correlation 
of A1cNow %A1C assay to a standardized laboratory. Clin Chem 
2005;51:A259–A.
37. Criel M, Jonckheere S, Langlois M. Evaluation of three 
hemoglobin A1c point of-care instruments. Acta Clinica 
Belgica: International Journal of Clinical and Laboratory 
Medicine 2015;70:S3.
38. Dupuy AM, Badiou S, Elong-Bertard C, Bargnoux AS, Cris-
tol JP. Analytical performance of the Axis-Shield Afinion for 
hemoglobin A1c measurement: impact of lot number. Clin Lab 
2014;60:369–76.
39. Ejilemele A, Unabia J, Ju H, Petersen JR. A1c Gear: laboratory 
quality HbA1c measurement at the point of care. Clin Chim Acta 
2015;445:139–42.
40. Estevez Fidalgo P, Pineiro Caamano A, Otero Santiago M, Garcia 
Aschauer JM, Lorenzo Freire MT, Espana Barrada R, et al. Valida-
tion of HbA1c results obtained with a point of care instrument. 
Clin Chem Lab Med 2014;52:S1523.
41. Ginde AA, Cagliero E, Nathan DM, Camargo CA, Jr. Point-of-care 
glucose and hemoglobin A1c in emergency department patients 
without known diabetes: implications for opportunistic screen-
ing. Acad Emerg Med 2008;15:1241–7.
42. Guerci B, Durain D, Leblanc H, Rouland JC, Passa P, Godeau T, 
et al. Multicentre evaluation of the DCA 2000 system for meas-
uring glycated haemoglobin. DCA 2000 Study Group. Diabetes 
Metab 1997;23:195–201.
43. Harris S, Tokmakejian S, Edmonds M, Webster-Bogaert S, 
Mahon J, Porter S, et al. Validation of the bayer DCA2000 (TM) as 
a point-of-care measure of glycosylated haemoglobin. Diabetes 
2000;49:A110–A.
44. Hawkins RC. Comparison of four point-of-care HbA1c analytical 
systems against central laboratory analysis. Singapore Med J 
2003;44:8–11.
45. Heng PY, Fun S, Chui KL, Taufik MA, Lew MY, Wong MS. An evalu-
ation of the performance of Roche Cobas b101 point-of-care 
system in the measurement of haemoglobin A1C. Clin Chem Lab 
Med 2015;53:S623.
46. Holmes EW, Ersahin C, Augustine GJ, Charnogursky GA, Gryzbac 
M, Murrell JV, et al. Analytic bias among certified methods for 
the measurement of hemoglobin A1c: a cause for concern? Am J 
Clin Pathol 2008;129:540–7.
47. Jiang F, Hou X, Lu J, Zhou J, Lu F, Kan K, et al. Assessment of the 
performance of A1CNow(+) and development of an error grid 
analysis graph for comparative hemoglobin A1c measurements. 
Diabetes Technol Ther 2014;16:363–9.
48. Jou JM, Bedini JL, Seuma J, Luna N, Kinder M. Evaluati on of the 
point of care a1cnow+ analy zer for HBA1C. International Journal 
of Laboratory Hematology 2013; Conference: 26th Interna-
tional Symposium on Technological Innovations in Laboratory 
Hematology, ISLH 2013 Toronto, ON Canada. Conference Start: 
20130510 Conference End: 20130512. Conference Publication: 
(var.pagings). 35:50.
49. Karami A, Baradaran A. Comparative evaluation of three differ-
ent methods for HbA1c measurement with High-performance 
liquid chromatography in diabetic patients. Adv Biomed Res 
2014;3:94.
50. Knaebel J, Irvin BR, Xie CZ. Accuracy and clinical utility of a point-
of-care HbA1c testing device. Postgrad Med 2013;125:91–8.
51. Leal S, Soto-Rowen M. Usefulness of point-of-care testing in the 
treatment of diabetes in an underserved population. J Diabetes 
Sci Technol 2009;3:672–6.
52. Leca V, Ibrahim Z, Lombard-Pontou E, Maraninchi M, Guieu 
R, Portugal H, et al. Point-of-care measurements of HbA1c: 
Simplicity does not mean laxity with controls. Diabetes Care 
2012;35:e85.
53. Lee K, Jun SH, Han M, Song SH, Park KU, Song WH, et al. Perfor-
mance evaluation of SD A1cCare as a HbA1c analyzer for point-
of-care testing. Clin Biochem 2015;48:625–7.
54. Lenters-Westra E, Slingerland RJ. Evaluation of the Quo-Test 
hemoglobin A1c point-of-care instrument: second chance. Clin 
Chem 2010;56:1191–3.
 - 10.1515/cclm-2016-0303
Downloaded from De Gruyter Online at 09/28/2016 01:03:45PM
via University of East Anglia
14      Hirst et al.: A systematic review and meta-analysis
55. Malkani S, Korpi-Steiner N, Rao LV. Reducing analytical variation 
between point-of-care and laboratory HbA1c testing. J Diabetes 
2013;5:192–6.
56. Manley SE, Hikin LJ, Round RA, Manning PW, Luzio SD, Dunseath 
GJ, et al. Comparison of IFCC-calibrated HbA1c from labora-
tory and point of care testing systems. Diabetes Res Clin Pract 
2014;105:364–72.
57. Marley JV, Oh MS, Hadgraft N, Singleton S, Isaacs K, Atkinson 
D. Cross-sectional comparison of point-ofcare with laboratory 
HbA 1c  in detecting diabetes in real-world remote Aboriginal set-
tings. BMJ Open 2015;5:e006277.
58. Martin DD, Shephard MD, Freeman H, Bulsara MK, Jones TW, 
Davis EA, et al. Point-of-care testing of HbA1c and blood glucose 
in a remote Aboriginal Australian community.[Erratum appears 
in Med J Aust 2005 Jun 20;182:656 Note: Bulsara, Max K 
[added]]. Med J Aust 2005;182:524–7.
59. Mattewal A, Aldasouqi S, Solomon D, Gossain V, Koller A. 
A1cNow InView: a new simple method for office-based 
glycohemoglobin measurement. J Diabetes Sci Technol 
2007;1:879–84.
60. Menendez-Valladares P, Fernandez-Riejos P, Sanchez-Mora 
C, Perez-Perez A, Sanchez-Margalet V, Gonzalez-Rodriguez 
C. Evaluation of a HbA1c point-of-care analyzer. Clin Biochem 
2015;48:686–9.
61. Nam S, Han H-R, Song H-J, Song Y, Kim KB, Kim MT. Utility of a 
point-of-care device in recruiting ethnic minorities for diabetes 
research with community partners. J Health Care Poor Under-
served 2011;22:1253–63.
62. Phillips SG, Nwagbo Y, Ashton K. Analytical evaluation of POCT 
HbA1c instruments. Clin Chem Lab Med 2014;52:eA324–5.
63. Rossi L, Della Bartola L, Giampietro O, Consani C, Pellegrini G, 
Matteucci E. Point-of-care hbA1c testing in a clinical setting: 
performance analysis. Clin Chem Lab Med 2015;53:S543.
64. Sanchez-Mora C, S Rodriguez-Oliva M, Fernandez-Riejos 
P, Mateo J, Polo-Padillo J, Goberna R, et al. Evaluation of 
two HbA1c point-of-care analyzers. Clin Chem Lab Med 
2011;49:653–7.
65. Schweitzer M, Cavan DA, Ziegler R, Cranston I, Parkin C, Wagner 
RS. Is HbA1c a reliable measure for assessing glycaemic control? 
Diabetologia 2012; Conference: 48th Annual Meeting of the 
European Association for the Study of Diabetes, EASD 2012 
Berlin Germany. Conference Start: 20121001 Conference End: 
20121005. Conference Publication: (var.pagings). 55:S404.
66. Shemesh T, Piers LS, O’Dea K. Use of the Bayer DCA 2000+ 
for the measurement of glycated haemoglobin in a remote 
 Australian Aboriginal community. Ann Clin Biochem 2003; 
40(Pt 5):566–8.
67. Shemesh T, Rowley KG, Shephard M, Piers LS, O’Dea K. Agree-
ment between laboratory results and on-site pathology testing 
using Bayer DCA2000+ and Cholestech LDX point-of-care meth-
ods in remote Australian Aboriginal communities. Clin Chim Acta 
2006;367:69–76.
68. Shephard M, Whiting M. Assessment of the practicability and 
analytical performance of a point-of-care affinity chromatog-
raphy haemoglobin A1c analyser for use in the non-laboratory 
setting. Ann Clin Biochem 2006;43(Pt 6):513–5.
69. Shimoda S, Maeda T, Furukawa N, Ichinose K, Taketa K, Igata M, 
et al. Evaluation of a new device for measurement of hemo-
globin A1c for Japanese subjects. Diabetology International 
2013;4:112–6.
70. Szymezak J, Leroy N, Lavalard E, Gillery P. Evaluation of the 
DCA Vantage analyzer for HbA 1c assay. Clin Chem Lab Med 
2008;46:1195–8.
71. Thueringer JT, Ishani A, Rector T, Greer N, Ercan-Fang N. Compar-
ison of a1c measurements from a home test device to a hospital 
laboratory. Diabetes 2012; Conference: 72nd Scientific Sessions 
of the American Diabetes Association Philadelphia, PA, United 
States. Conference Start: 20120608 Conference End: 20120612. 
Conference Publication: (var.pagings). 61:A218.
72. Twomey PJ, Rayman G, Pledger DR. Implications of different 
DCCT-aligned HbA(1c) methods on GMS clinical indicators. Dia-
betic Med 2008;25:97–100.
73. Wan Mohd Zin RM, Ahmad Kamil ZI, Tuan Soh TR, Embong M, 
Wan Mohamud WN. Haemoglobin A1c: comparing performance 
of two point of care devices with laboratory analyser. BMC Res 
Notes 2013;6:540.
74. Wehmeier M. Evaluation of POCT HBA1C analyzer innovastar for 
use in diabetes clinics. Clin Chem Lab Med 2012; Conference: 
Congress of Clinical Chemistry and Laboratory Medicine 9th 
Annual Meeting of the German Society for Clinical Chemistry and 
Laboratory Medicine, DGKL 2012 Mannheim Germany. Confer-
ence Start: 20120926 Conference End: 20120929. Conference 
Publication: (var.pagings). 50:A266–7.
75. Williams PF, Tan K, Sherfan J, Woolnough C, Lin E, Brown M, 
et al. Comparison of three point of care (POC) HbA1c devices 
with cation exchange and capillary electrophoresis. Diabetes 
2014;63:A220.
76. Zhou R, Tong Q, Zuo C, Song ZX, Ma HA, Yue YH, et al. Point-of-
care testing of HbA1C is traceable to IFCC reference method by 
external calibration. Clin Chim Acta 2014;433:249–53.
77. CAP. College of American Pathologists (CAP) GH5 Survey Data 
2016 [09/06/2016]. Available at: http://www.ngsp.org/CAP/
CAP16a.pdf.
78. Ferreras Amez JM, Aldea Molina E, Ortega Jimenez N, Guardia 
Sancho L, Gamez Gomez MA, Blasco Valle M. Assessment of 
glycosylated hemoglobin in capillary blood compared to venous 
blood. [Spanish]. Atencion Primaria 2010;42:60–1.
79. Keramati T, Razi F, Tootee A, Larijani B. Comparability of hemo-
globin A1c level measured in capillary versus venous blood sam-
ple applying two point-of-care instruments. J Diabetes Metab 
Disord 2014;13:94.
80. NGSP. Harmonising Hemoglobin A1c Testing 2010 [24/8/2015]. 
Available at: http://www.ngsp.org/.
81. Weykamp C, John G, Gillery P, English E, Ji L, Lenters-Westra 
E, et al. Investigation of 2 models to set and evaluate quality 
targets for hb a1c: biological variation and sigma-metrics. Clin 
Chem 2015;61:752–9.
82. Ferenczi A, Reddy K, Lorber DL. Effect of immediate hemoglobin 
A1c results on treatment decisions in office practice. Endocr 
Pract 2001;7:85–8.
83. Miller CD, Barnes CS, Phillips LS, Ziemer DC, Gallina DL, Cook CB, 
et al. Rapid A1c availability improves clinical decision-making in 
an urban primary care clinic. Diabetes Care 2003;26:1158–63.
84. Lenters-Westra E, Roraas T, Schindhelm RK, Slingerland RJ, 
 Sandberg S. Biological variation of hemoglobin A1c: consequences 
for diagnosing diabetes mellitus. Clin Chem 2014;60:1570–2.
Supplemental Material: The online version of this article  
(DOI: 10.1515/cclm-2016-0303) offers supplementary material, 
available to authorized users.
 - 10.1515/cclm-2016-0303
Downloaded from De Gruyter Online at 09/28/2016 01:03:45PM
via University of East Anglia
